Different features of acute myeloid leukemia stem cell quantification in intensively treated patients
In acute myeloid leukemia, the burden of CD34+CD38- leukemia stem cells (LSC) has prognostic value at diagnosis and after induction chemotherapy. Since different methods of LSC quantification have been proposed, we determined the prognostic value on overall survival and incidence of relapse of thes...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2025-04-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/12046 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850173557874622464 |
|---|---|
| author | Lok Lam Ngai Tom Reuvekamp Diana Hanekamp Fleur Janssen Laura Oudshoorn-van Marsbergen Jannemieke Carbaat-Ham Maaike A.M. Hofland Mona M.H.E. Fayed Angèle Kelder Willemijn J. Scholten Alexander N. Snel Costa Bachas Jesse M. Tettero Dimitri A. Breems Thomas Fischer Bjørn T. Gjertsen Laimonas Griškevičius Gunnar Juliusson Arjan A. van de Loosdrecht Johan A. Maertens Markus G. Manz Thomas Pabst Jakob R. Passweg Kimmo Porkka Peter J.M. Valk Patrycja Gradowska Bob Löwenberg Gert J. Ossenkoppele David C. de Leeuw Jacqueline Cloos |
| author_facet | Lok Lam Ngai Tom Reuvekamp Diana Hanekamp Fleur Janssen Laura Oudshoorn-van Marsbergen Jannemieke Carbaat-Ham Maaike A.M. Hofland Mona M.H.E. Fayed Angèle Kelder Willemijn J. Scholten Alexander N. Snel Costa Bachas Jesse M. Tettero Dimitri A. Breems Thomas Fischer Bjørn T. Gjertsen Laimonas Griškevičius Gunnar Juliusson Arjan A. van de Loosdrecht Johan A. Maertens Markus G. Manz Thomas Pabst Jakob R. Passweg Kimmo Porkka Peter J.M. Valk Patrycja Gradowska Bob Löwenberg Gert J. Ossenkoppele David C. de Leeuw Jacqueline Cloos |
| author_sort | Lok Lam Ngai |
| collection | DOAJ |
| description |
In acute myeloid leukemia, the burden of CD34+CD38- leukemia stem cells (LSC) has prognostic value at diagnosis and after induction chemotherapy. Since different methods of LSC quantification have been proposed, we determined the prognostic value on overall survival and incidence of relapse of these methods across ELN2017 risk groups, using data from the HOVON-SAKK132 trial. In addition, we have evaluated the optimal number of acquired white blood cells for accurate LSC detection and the prognostic value of individual LSC markers. Results show that acquiring 1 million white blood cells is essential for accurate LSC-negativity assessment. Among different LSC markers, CD44 overexpression on CD34+CD38- cells was the only insignificant marker in our panel. Testing the impact of several published variations on the analysis for LSC assessments on prognostic value for overall survival and cumulative incidence of relapse, showed marginal differences, demonstrating the robust prognostic value of LSC burden. For further clinical implementation, the optimal LSC assessment may differ among ELN risk groups. In conclusion, LSC burden is a robust prognostic factor and insight in the different methods of LSC definition can facilitate the clinical implementation.
|
| format | Article |
| id | doaj-art-7efccb4512a14e12b4a46fa6c6d8edde |
| institution | OA Journals |
| issn | 0390-6078 1592-8721 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Ferrata Storti Foundation |
| record_format | Article |
| series | Haematologica |
| spelling | doaj-art-7efccb4512a14e12b4a46fa6c6d8edde2025-08-20T02:19:50ZengFerrata Storti FoundationHaematologica0390-60781592-87212025-04-01999110.3324/haematol.2024.287090Different features of acute myeloid leukemia stem cell quantification in intensively treated patientsLok Lam Ngai0Tom Reuvekamp1Diana Hanekamp2Fleur Janssen3Laura Oudshoorn-van Marsbergen4Jannemieke Carbaat-Ham5Maaike A.M. Hofland6Mona M.H.E. Fayed7Angèle Kelder8Willemijn J. Scholten9Alexander N. Snel10Costa Bachas11Jesse M. Tettero12Dimitri A. Breems13Thomas Fischer14Bjørn T. Gjertsen15Laimonas Griškevičius16Gunnar Juliusson17Arjan A. van de Loosdrecht18Johan A. Maertens19Markus G. Manz20Thomas Pabst21Jakob R. Passweg22Kimmo Porkka23Peter J.M. Valk24Patrycja Gradowska25Bob Löwenberg26Gert J. Ossenkoppele27David C. de Leeuw28Jacqueline Cloos29Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, AmsterdamAmsterdam UMC location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands; Amsterdam UMC location Universiteit van Amsterdam, Department of Hematology, AmsterdamAmsterdam UMC location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands; Erasmus University Medical Center, Department of Hematology, RotterdamAmsterdam UMC location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, AmsterdamAmsterdam UMC location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, AmsterdamAmsterdam UMC location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, AmsterdamAmsterdam UMC location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, AmsterdamAmsterdam UMC location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, AmsterdamAmsterdam UMC location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, AmsterdamAmsterdam UMC location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, AmsterdamAmsterdam UMC location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, AmsterdamAmsterdam UMC location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, AmsterdamAmsterdam UMC location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, AmsterdamZiekenhuis aan de Stroom, Department of Hematology, AntwerpOtto von Guericke University Hospital Magdeburg, MagdeburgHaukeland University Hospital, BergenVilnius University Hospital Santaros Klinikos and Vilnius University, Vilnius, LithuaniaSkanes University Hospital, LundAmsterdam UMC location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, AmsterdamUniversity Hospital Gasthuisberg, LeuvenUniversity Hospital, Zurich, Switzerland; Swiss Group for Clinical Cancer Research (SAKK)Swiss Group for Clinical Cancer Research (SAKK); Department of Medical Oncology, Inselspital; University Hospital, BernSwiss Group for Clinical Cancer Research (SAKK); Department of Medical Oncology, Inselspital; University Hospital, Bern, Switzerland; University Hospital, BaselHelsinki University Hospital Cancer Center, HelsinkiErasmus University Medical Center, Department of Hematology, RotterdamHOVON Foundation, Rotterdam, the Netherlands; Department of Hematology, Erasmus MC Cancer Institute, RotterdamErasmus University Medical Center, Department of Hematology, Rotterdam, Netherlands; Department of Hematology, Erasmus MC Cancer Institute, RotterdamAmsterdam UMC location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, AmsterdamAmsterdam UMC location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, AmsterdamAmsterdam UMC location Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam In acute myeloid leukemia, the burden of CD34+CD38- leukemia stem cells (LSC) has prognostic value at diagnosis and after induction chemotherapy. Since different methods of LSC quantification have been proposed, we determined the prognostic value on overall survival and incidence of relapse of these methods across ELN2017 risk groups, using data from the HOVON-SAKK132 trial. In addition, we have evaluated the optimal number of acquired white blood cells for accurate LSC detection and the prognostic value of individual LSC markers. Results show that acquiring 1 million white blood cells is essential for accurate LSC-negativity assessment. Among different LSC markers, CD44 overexpression on CD34+CD38- cells was the only insignificant marker in our panel. Testing the impact of several published variations on the analysis for LSC assessments on prognostic value for overall survival and cumulative incidence of relapse, showed marginal differences, demonstrating the robust prognostic value of LSC burden. For further clinical implementation, the optimal LSC assessment may differ among ELN risk groups. In conclusion, LSC burden is a robust prognostic factor and insight in the different methods of LSC definition can facilitate the clinical implementation. https://haematologica.org/article/view/12046 |
| spellingShingle | Lok Lam Ngai Tom Reuvekamp Diana Hanekamp Fleur Janssen Laura Oudshoorn-van Marsbergen Jannemieke Carbaat-Ham Maaike A.M. Hofland Mona M.H.E. Fayed Angèle Kelder Willemijn J. Scholten Alexander N. Snel Costa Bachas Jesse M. Tettero Dimitri A. Breems Thomas Fischer Bjørn T. Gjertsen Laimonas Griškevičius Gunnar Juliusson Arjan A. van de Loosdrecht Johan A. Maertens Markus G. Manz Thomas Pabst Jakob R. Passweg Kimmo Porkka Peter J.M. Valk Patrycja Gradowska Bob Löwenberg Gert J. Ossenkoppele David C. de Leeuw Jacqueline Cloos Different features of acute myeloid leukemia stem cell quantification in intensively treated patients Haematologica |
| title | Different features of acute myeloid leukemia stem cell quantification in intensively treated patients |
| title_full | Different features of acute myeloid leukemia stem cell quantification in intensively treated patients |
| title_fullStr | Different features of acute myeloid leukemia stem cell quantification in intensively treated patients |
| title_full_unstemmed | Different features of acute myeloid leukemia stem cell quantification in intensively treated patients |
| title_short | Different features of acute myeloid leukemia stem cell quantification in intensively treated patients |
| title_sort | different features of acute myeloid leukemia stem cell quantification in intensively treated patients |
| url | https://haematologica.org/article/view/12046 |
| work_keys_str_mv | AT loklamngai differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT tomreuvekamp differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT dianahanekamp differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT fleurjanssen differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT lauraoudshoornvanmarsbergen differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT jannemiekecarbaatham differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT maaikeamhofland differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT monamhefayed differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT angelekelder differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT willemijnjscholten differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT alexandernsnel differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT costabachas differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT jessemtettero differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT dimitriabreems differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT thomasfischer differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT bjørntgjertsen differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT laimonasgriskevicius differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT gunnarjuliusson differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT arjanavandeloosdrecht differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT johanamaertens differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT markusgmanz differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT thomaspabst differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT jakobrpassweg differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT kimmoporkka differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT peterjmvalk differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT patrycjagradowska differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT boblowenberg differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT gertjossenkoppele differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT davidcdeleeuw differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients AT jacquelinecloos differentfeaturesofacutemyeloidleukemiastemcellquantificationinintensivelytreatedpatients |